EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach

Hussein Awada iD, Carmelo Gurnari iD, Zhuoer Xie, Jan Philipp Bewersdorf iD, Amer M Zeidan

Cancers · 12.04.2023 · 15 (8) · 2248

DOI: 10.3390/cancers15082248 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.04.2023. Verfasst von Hussein Awada und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, Edward P. Evans Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypomethylating agents (HMA) such as azacitidine and decitabine are a mainstay in the current management of patients with myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML) as either single agents or in multidrug combinations. Resistance to HMA is not uncommon, and it can result due to several tumor cellular adaptations. Several clinical and genomic factors have been identified as predictors of HMA resistance. However, the management of MDS/AML patients after the failure of HMA remains challenging in the absence of standardized guidelines. Indeed, this is an area of active research with several potential therapeutic agents currently under development, some of which have demonstrated therapeutic potential in early clinical trials, especially in cases with particular mutational characteristics. Here, we review the latest findings and give a rational approach for such a challenging scenario.

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukemiahypomethylating agentsmyelodysplastic syndromes/neoplasms

Autor:innen und Institutionen

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
  • Department of Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Comprehensive Cancer Center, New York, NY 10065, USA.
  • Section of Hematology, Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, CT 06511, USA.

ORCID-Profile: Hussein Awada, Carmelo Gurnari, Jan Philipp Bewersdorf

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • Edward P. Evans Foundation

Zitieren

APA

Awada, H., Gurnari, C., Xie, Z., Bewersdorf, J. P., & Zeidan, A. M. (2023). What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers, 15(8), 2248. https://doi.org/10.3390/cancers15082248

Vancouver

Awada H, Gurnari C, Xie Z, Bewersdorf JP, Zeidan AM. What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers. 2023;15(8):2248. doi:10.3390/cancers15082248

BibTeX
@article{Awada2023,
  author = {Awada, Hussein and Gurnari, Carmelo and Xie, Zhuoer and Bewersdorf, Jan Philipp and Zeidan, Amer M},
  title = {What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {8},
  pages = {2248},
  doi = {10.3390/cancers15082248}
}
Kostenlos starten →